Pay in 4 interest-free payments of $6.85 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Individuals with T2DM frequently have multiple cardiovascular risk factors, including obesity (32.9%), hypertension (32-80%), and dyslipidemia (39%) ( The association between glycemic control and cardiovascular outcomes in DM patients has been long studied ( To address these challenges, novel pharmacological therapies such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged, offering cardioprotective benefits ( The aim of this review is to enhance our understanding of the role of SGLT-2i and GLP-1 RAs in managing patients with T2DM and CVD
It further elaborates on the core mechanisms underlying platinum accumulation-mediated multi-organ toxicity, including nephrotoxicity, neurotoxicity, and ototoxicity
Q: Who might not benefit from glutathione IV therapy
We need rigorous models that distinguish cancer risk from progression, as well as studies that carefully vary treatment timing, duration and combinations with standard therapies
US$ 27.22
/assets/images/provider/photos/2800172.png)
US$ 22.98
US$ 20.74
